tbuckley/cabot-search huggingface dataset:
525P Immuno markers in newly glioblastoma patients underwent Stupp protocol after neurosurgery
Authors: L. Gurrieri, L. Mercatali, T. Ibrahim, V. Fausti, M. Dall'Agata, M.N. Riva, N. Ranallo, G. Pasini, M. Tazzari, F. Foca, D. Bartolini, L. Riccioni, C. Cavatorta, F. Morigi, J. Bulgarelli, C. Cocchi, V. Ghini, L. Tosatto, L. Ridolfi
Journal: Annals of Oncology (2023)
529P Post-marketing surveillance data from patients ≥70 years of age with central nervous system malignancies treated with Tumor Treating Fields (TTFields) therapy between 2011–2022
Authors: W. Shi, M. Glas, M.M. Mrugala, F.M. Iwamoto, R.V. Lukas, J. Palmer, J. Suh
Journal: Annals of Oncology (2023)
539P Epidemiology and prognostic factors of lung cancer and brain metastases: A 10-year retrospective population cohort study in Girona, Spain
Authors: E. Teixidor Vilà, A. Sanvisens, A. Hernandez Martinez, M. Puigdemont, J. Trallero, A. Vidal-Vila, È.S. Sais Girona, J. Sabaté, E. Cuyàs, S. Verdura, V. Pineda, J. Puig-Alcántara, J.A. Menendez, R. Marcos-Gragera, J. Bosch-Barrera
Journal: Annals of Oncology (2023)
538P Single-center retrospective analysis of patients with brain metastases included in early phase clinical trials
Authors: G. Pretelli, K.I. Rojas Laimito, G. Alonso, M.J. Lostes Bardaji, A. Hernando Calvo, V. Galvao, A. Oberoi, B. Ortega Morillo, O. Saavedra Santa Gadea, J. Ginard Moya, C. Saura Manich, M.E. Elez Fernandez, C. Ortiz, E. Muñoz Couselo, I. Braña, A. Callejo Perez, J. Carles Galceran, E. Felip, E. Garralda, M. Vieito Villar
Journal: Annals of Oncology (2023)
506MO A phase I dose-expansion cohort of SYHA1813, a vascular endothelial growth factor receptor (VEGFR) 1-3 /colony-stimulating factor 1 receptor (CSF1R) inhibitor, in patients (pts) with recurrent meningioma
Authors: W. Li, Z. Kang, Z. Wu, S. Li, M. Huang, W. Pu, X. Yang, J. Lin, M. Liu
Journal: Annals of Oncology (2023)
509P Spatial analysis of tumor-associated macrophages within the tumor microenvironment of primary tumors and matched brain metastases
Authors: M. Kleinberger, D. Cifci, C. Paiato, E. Tomasich, M. Mair, A. Steindl, Z. Carrero, L. Berchtold, J.A. Hainfellner, L. Müllauer, G. Heller, J.N. Kather, M. Preusser, A.S. Berghoff
Journal: Annals of Oncology (2023)
542P Drug screening in Li-Fraumeni syndrome brain tumor models
Authors: A.S. Kolodziejczak, F. Selt, H. Peterziel, N. Jamaladdin, N. Mack, K. Maaß, C. Meulenbroeks, M. Kool, C. Herold-Mende, A. El Damaty, I. Oehme, D.T.W. Jones, K.W. Pajtler, C. Kratz, S.M. Pfister, O. Witt, T. Milde
Journal: Annals of Oncology (2023)
507MO REGOMA-OS: A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients
Authors: G. Lombardi, I. Desideri, V. Villani, M. Simonelli, M. Buglione, S. Chiesa, E. Franceschi, P. Gaviani, I. Stasi, C. Caserta, S. Brugnara, I.R. Lolli, E. Bennicelli, P. Bini, A. Cuccu, None S. scoccianti, G. Magni, M. Caccese, G. De Salvo, V. Zagonel
Journal: Annals of Oncology (2023)
513P Cyclin pathway in oligodendrogliomas IDH mut and 1p/19q codeleted
Authors: M.A. Vaz Salgado, J.M. Sepulveda Sanchez, J. Earl, A. Perez, H. Pian, Y. Ruano, J. Gutierrez, A. Carrato Mena, L.L. Ley, M. Villamayor, V. López, I. Martínez Delfrade, V. Albarrán, J. Chamorro-Perez, D.I. Rosero Rodriguez, B.I. Morón, None A.H. lain
Journal: Annals of Oncology (2023)
517P Differentiating IDH-wildtype and IDH-mutant high grade gliomas with deep learning
Authors: K.J. Hewitt, C.M.L. Loeffler, M. van Treeck, H. Muti, G. Veldhuizen, O. Saldanha, L. Bejan, T. Millner, S. Brandner, J.N. Kather
Journal: Annals of Oncology (2023)
536P Safety and efficacy of silibinin in patients with brain metastases after stereotactic radiosurgery (SRS): The SUSTAIN trial
Authors: N. Bertini, L. Visani, I. Bonaparte, M.G. Carnevale, B. Bettazzi, A. Romei, C. Becherini, D. Greto, B. Detti, I. Meattini, L. Livi, I. Desideri
Journal: Annals of Oncology (2023)
511P Immunodisruptive conditions and glioma diagnosis: 24-year retrospective study of an under-recognized scenario
Authors: S. Cabezas-Camarero, R. Pérez-Alfayate, M.J. Sotelo Lezama, P. Pérez Segura
Journal: Annals of Oncology (2023)

Disruption of the immune system is known to favor carcinogenesis and cancer breakthrough. Gliomas constitute de most prevalent primary malignant brain tumors. We aimed to study the occurrence of immune disruptive conditions (IDC) in patients with gliomas at our institution. Retrospective study of patients (pts) diagnosed with a glioma at Hospital Clínico Universitario San Carlos, Madrid (Spain). IDCs included autoimmune diseases (AID), organ transplantation (OT) requiring chronic immunosuppressive therapy (IST), and hematological malignancies (HM). A descriptive study, as well as time since IDC, time under IST, and progression-free survival (PFS) and overall survival (OS) since glioma diagnosis were analyzed. Within the period January 1999 – April 2023, among 481 patients diagnosed with a glioma, 30 (6.2%) patients harbored IDCs. Male/Female: 14/16. Age: 63y (32-83). WHO 5th Ed.: IDH-WT GB: n=26 (MGMTmeth: 50%, MGMTunmeth: 50%), IDH-MUT Astro: n=3, Pleomorphic xanthoastro: n=1. Frontal: n=14, Temporal: n=8, Parietal: n=6. Unilobar: n=23, Bilobar: n=4, Trilobar: n=1. Right: n=8, Left: n=19, Bilateral: n=3. Resection: GTR=8, STR=1, Partial=3, Biopsy=14. RTx=20 pts, CRTx=18, Adj CTx=13. Median PFS and OS since diax were 9 and 10 months (m), respectively. No. of IDCs: 1 (n=21 pts), ≥ 2 (n=9 pts). IDC type: AID (n=27 pts) among which: endocrine (4: Addison, Hypothyroidism, Hashimoto's thyroiditis), respiratory (7: asthma, sarcoidosis, alergic rinoconjunctivitis), cutaneous (7: chronic eccema, psoriasis), neurological (4: multiple sclerosis, Guillain-Barré), digestive system (2: inflammatory bowel disease), rheumatological (13: Horton's disease, Sjöegren's syndrome, systemic lupus erithematosus, uveitis, vasculitis); HM (1: chronic lymphocytic leukaemia); OT (2: renal). IST for IDCs used in 20 pts (systemic IST in 17). Median time since IDC: 101 m (10-411). Median time under IST: 108 m (0-283). Within a large 24-year long retrospective series, a minority of pts with glioma harbored an IDC, most commonly rheumatological, respiratory, or cutaneous. Studies should be conducted to unveil if gliomas occurring in pts with IDCs are biologically and immunologically distinct.
541P A multicenter study evaluating the clinical and molecular characteristics of adult patients with diffuse midline and non-midline K27M altered gliomas
Authors: M.A. Mazariegos Rubi, A. Ramos Fresnedo, M.E. Jentoft, D. Trifiletti, K. Chaichana, I. Otero Blas, T. Burns, A. Porter, W.J. Sherman, J.L. Campian, A. Quinones Hinojosa
Journal: Annals of Oncology (2023)
505MO A phase 0/Ib study of AZD1390 plus radiotherapy in recurrent glioblastoma patients
Authors: N. Sanai, S. Desai, T. Margaryan, C. Lo Cascio, M. Elliott, J. Molloy, J. Harmon, A. Hong, E. Luna Melendez, J. Wanebo, K. Braun, W. Kennedy, M. Garcia, W. Yoo, A. Tovmasyan, A-C. Tien, S.N. Mehta
Journal: Annals of Oncology (2023)
498O INDIGO: A randomized, double-blinded, phase III study of vorasidenib versus placebo in IDH1 or IDH2 low-grade glioma
Authors: D. Blumenthal, I.K. Mellinghoff, M.J. van den Bent, M. Touat, K. Peters, J. Clarke, J. Mendez, L. Welsh, W. Mason, A.F. Hottinger, J.M. Sepulveda Sanchez, W. Wick, R. Soffietti, A. Tron, D. Zhao, S. Pandya, L. Steelman, I. Hassan, P. Wen, T. Cloughesy
Journal: Annals of Oncology (2023)
CN76 Consensus views on research priorities for cancer survivorship in older adulthood: A Delphi study
Authors: A. Drury, A. O'Brien, L. O'Connell, S. Cosgrave, M. Hannan, None C. smyth, K. Fessele, S. Sheehan, M. Harkin, L. Rogers
Journal: Annals of Oncology (2023)
CN80 Mindfulness-based stress reduction as continuing educational course for oncology team welfare
Authors: E. Gianotti, G. Razzini, R. Ferrari, D. Barbieri, I. Bernardini, M. Bini, K. Cagossi, T. Cipriano, M. Delgaudio, V. Fantuzzi, U. Ferrari, L. Lombardo, A. Pietramaggiori, R. Porumb, C. Mucciarini
Journal: Annals of Oncology (2023)
CN86 Advanced breast cancer care for nurses (ABC4Nurses): A mixed-methods evaluation of an online educational programme
Authors: S. Sheehan, C. Díez de los Ríos de la Serna, G. Bagcivan, M. Dowling, G. Kotronoulas, A. Shewbridge, S. Erdem, V. Aroyo, B. Radia, T. Wiseman, A. Drury
Journal: Annals of Oncology (2023)
500O Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study
Authors: M. Vieito Villar, J.M. Sepúlveda Sánchez, V. Moreno Garcia, G. Lombardi, A. Stradella, R.H. Dahlrot, C.A. Haslund, M. Geurts, E. Pineda, P. Brandal, F.Y.F.L. De Vos, M.A. Vaz Salgado, M. Martinez Garcia, M. Macchini, B. Amoroso, T. Sanchez, B. Hanna, X. Li, Z. Nikolova, M. Simonelli
Journal: Annals of Oncology (2023)
501O Glasdegib in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Phase Ib/II GEINO 1602 trial
Authors: M.Á. Vaz, S. del Barco, J.M. Sepúlveda, M. Alonso, E. Pineda, C. Balana, M. Martínez-García, R. Gironés
Journal: Annals of Oncology (2023)
552O FOxTROT: Results of embedded phase II evaluating the addition of panitumumab (pan) to neo-adjuvant FOLFOX for patients (pts) with KRAS-wt colon cancer (CC) with extended biomarker panel
Authors: J. Seligmann, D. Morton, M. Seymour, F. Elliott, K. Handley, B. Glimelius, C. Williams, G. Hemmings, D. Bottomley, R. Gray, P. Quirke, L. Magill, A.D. Beggs, N. West
Journal: Annals of Oncology (2023)
569P Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
Authors: F.A. Sinicrope, G. Nelson, B. Saberzadeh Ardestani, G. Park, Y. Lim, D. Yan, K. Shanmugam, S. Alberts, Q. Shi, C-Y. Ock, R. Pai, D. Segovia
Journal: Annals of Oncology (2023)
560MO Maintenance with 5FU/LV-Aflibercept after induction with FOLFIRI-Aflibercept vs FOLFIRI-Aflibercept until progression in older patients (pts) in 2nd line metastatic colorectal cancer (mCRC): The randomized AFEMA trial
Authors: P. García Alfonso, M.E. Elez Fernandez, J. Soto Alsar, D. Paez, A. Fernandez Montes, B. Grana Suarez, A. Salud, A. Yubero Esteban, M.A. Gomez España, I. Macias Declara, G.A. Quintero Aldana, C. Lopez Lopez, T. Fernandez Rodriguez, M.C. Gravalos Castro, E. González-Flores, M. Guix Arnau, B. García Paredes, J.J. Reina Zoilo, J. Sastre Varela, E. Aranda Aguilar
Journal: Annals of Oncology (2023)
575P Impact of immunological alterations and post-operative biomarkers on long-term outcomes in patients with locally advanced rectal cancer: Results from the STAR-01 study cohort
Authors: F. Negri, L. Gnetti, L. Bottarelli, N. Campanini, M.E. Negru, S. Tamberi, F. Bergamo, M. Frisinghelli, G. Masi, G. Chiaulon, A. Tagliagambe, S. Siena, M. Petric, A. Morabito, G.L. Frassineti, D.C. Corsi, L. Rimassa, None G.L. de'Angelis, L. Boni, C. Aschele
Journal: Annals of Oncology (2023)
558MO Circulating tumor (ct)DNA as a prognostic biomarker in patients (pts) with resected colorectal cancer (CRC): An updated 24 months (mos) disease free survival (DFS) analysis from GALAXY study (CIRCULATE-Japan)
Authors: Y. Nakamura, D. Kotani, M. Saori, H. Yukami, J. Watanabe, N. Akazawa, K. Kataoka, K. Hirata, K. Yamazaki, K-H. Yeh, G. Laliotis, V. Aushev, A. Jurdi, M. Kotaka, H. Bando, H. Taniguchi, I. Takemasa, T. Kato, T. Yoshino, E. Oki
Journal: Annals of Oncology (2023)
499O A phase II study to explore the efficacy and safety of FCN-159 in recurrent or progressive pediatric low-grade glioma (pLGG) with MAPK pathway-activated
Authors: W. Li, Y. Mao, Z. Kang, W. Hua, S. Li, Z. Wu, H. Liu, J. Hu, J. Guo, W. Zhong, X. Wang
Journal: Annals of Oncology (2023)
600P Effectiveness and safety of rectal arterial infusion chemotherapy combined with anti-PD1 antibody for microsatellite stable locally advanced rectal cancer: Early outcome report of a two-stage, single armed, phase II study (RAIC)
Authors: Y. Jiao, J. Li, X. Kong, C. Liu, S. Han, L. Wang, Y. Hu, H. Hu, Y. Song, Z. Wang, J. He, Q. Deng, H. Cao, K. Ding
Journal: Annals of Oncology (2023)
553O Prognostic value of KRAS and BRAF mutations in microsatellite stable (MSS) and unstable (MSI) stage III colon cancer: An ACCENT/IDEA pooled analysis of 7 trials
Authors: J. Taieb, L. Pederson, F.A. Sinicrope, S. Lonardi, S. Alberts, T. George, L. Saltz, G. Yothers, R. Goldberg, R. Kerr, T. Yoshino, E. Van Cutsem, S. Ogino, T. André, P. Laurent-Puig, Q. Shi
Journal: Annals of Oncology (2023)
567P Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
Authors: E.S. Bergen, C. Canton, M. Boulin, K. Le Malicot, J. Bennouna, D. Gonzalez, L. Mineur, R. Coriat, O. Bouche, C. Lepage, J. Taieb
Journal: Annals of Oncology (2023)
562P Quantifying the effect of colonoscopy and polypectomy rates in stage shift of colorectal cancer and reduced need for adjuvant chemotherapy
Authors: M. Sarofim, A. Ashrafizadeh, A. Gill, K. De Silva, J. Evans, S. Clarke, N. Pavlakis, I. Norton, A. Engel
Journal: Annals of Oncology (2023)
549O Adagrasib with or without cetuximab in patients with KRASG12C-mutated colorectal cancer (CRC): Analysis of tumor biomarkers and genomic alterations
Authors: M.S. Pelster, R. Yaeger, S.J. Klempner, S-H.I. Ou, A.I. Spira, P.A. Jänne, N.V. Uboha, Y.A. Gaffar, G. Newman, C.P. Paweletz, G.A. Heavey, L. Alejandro, T. Kheoh, K. Anderes, H. Der Torossian, J.G. Christensen, J. Weiss
Journal: Annals of Oncology (2023)
572P Neoantigen heterogeneity among subtypes in colorectal cancer
Authors: F. Li, T. Luo, L. Nunes, M. Wu, K. Hammarström, E. Lundin, I. Ljuslinder, A. Mezheyeuski, P-H. Edqvist, A. Löfgren-Burström, C. Zingmark, S. Edin, F. Ponten, R. Palmqvist, K. Wu, B. Glimelius, T. Sjöblom, C. Lin
Journal: Annals of Oncology (2023)
559MO Rechallenge with EGFR inhibitors in ctDNA RAS/BRAF wild type refractory metastatic colorectal cancer: Individual patients’ data pooled analysis from 4 phase II trials
Authors: D. Ciardiello, G. Mauri, D. Rossini, V. Famiglietti, G. Martini, S. Napolitano, S. Del Tufo, M.G. Zampino, A. Avallone, F. Pietrantonio, S. Lonardi, D. Santini, G. Masi, S. Siena, A. Bardelli, F. Ciardiello, C. Cremolini, A. Sartore Bianchi, T. Troiani, E. Martinelli
Journal: Annals of Oncology (2023)
573P Multiparameter immunoprofiling reveals independent prognostic value of intraepithelial CD8 and intrastromal FoxP3 infiltrate in stage II/III colorectal cancer: Analysis of 3,409 cases from the SCOT and QUASAR2 trials
Authors: D.N. Church, A. Frei, A. McGuigan, R. Sinha, A. Harkin, T.J. Iveson, M.P. Saunders, J. Hay, J. Edwards, O.J. Sansom, C. Kelly, R. Kerr, D.J. Kerr, E. Domingo, V.H. Koelzer
Journal: Annals of Oncology (2023)
579P A clinico-imaging predictive artificial intelligence model of relapse in colon cancer using baseline CT scans
Authors: A. Bueno Gómez, M. Busto, A. Alcolado Jaramillo, X. Monzonis Hernandez, A. Fuster-Matanzo, J.A. Carbonell-Asins, A. Gómez-Alderete, F. Gimeno-Valiente, J. Lozano, J. Vidal Barrull, M.G. Bartolomé, P. Moreno Ruiz, A. Jiménez Pastor, V. Doldán-Martelli, A. Cuñat Romero, F. Bellvis Bataller, J. Gibert, C. Montagut Viladot, A. Cervantes, N. Tarazona Llavero
Journal: Annals of Oncology (2023)
565P Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
Authors: D.M. Gisder, I. Tischoff, J. Christmann, I. Feder, E. Schlageter, S. Wisser, C. Lugnier, A-L. Kraeft, H. Wolters, V. Heuer, B. Sargin, S. Hollerbach, C. Lamberti, A. Tannapfel, A. Reinacher-Schick
Journal: Annals of Oncology (2023)
581P The effect of exercise intervention on defecation related symptoms of colorectal cancer patients a randomized controlled trial
Authors: J. Jeon, D-H. Park, Y.J. LEE, T.H. Lee, E. Kim, C. Oh, R. Park, J.W. Kang, S. Jun, K. Chiho, S. Yeon
Journal: Annals of Oncology (2023)
590P Assessment of circulating tumor (ct)DNA in patients (pts) with locally advanced rectal cancer (LARC) pts treated with neoadjuvant therapy (NAT)
Authors: C. Molinari, G. Marisi, G. Laliotis, E. Spickard, I.G. Rapposelli, E. Petracci, G.V. George, S. Sharma, A. Jurdi, H. Sethi, M.C. Liu, P. Ulivi, M. Canale, L. Saragoni, R. Panzacchi, G.L. Frassineti, M. Muratore, A. Romeo, G. Martinelli, A. Passardi
Journal: Annals of Oncology (2023)
586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial
Authors: D. Day, A. Starus, V. Gebski, J. Simes, T. Hayes, S. Padinharakam, A.H. Strickland, K. Briscoe, S. Varma, M. Barnet, C. Jackson, L.G. Horvath, T.J. Price, N. Tebbutt, B. Karki, C.I. Diakos, J. Chia, H.C. Toh, F.S. Jones, E. Segelov
Journal: Annals of Oncology (2023)
587P Short lead time and high rates of concomitant radiographic recurrences for ctDNA-based minimal residual disease assays colorectal cancer (CRC) during surveillance: Results from the MD Anderson INTERCEPT program
Authors: M. Eluri, N.A. Dasari, G. Maddalena, A. Bent, A.J. Pellatt, A. Balachandran Pillai, K. Alfaro-Munoz, R.J. Kell, T. Newhook, A. Uppal, T. Konishi, V. Morris, E.S. Kopetz
Journal: Annals of Oncology (2023)
591P Survival and benefit of adjuvant chemotherapy (ACT) by circulating tumor DNA (ctDNA)-based genomic profile and molecular residual disease (MRD) in resectable colorectal oligometastases (CRM): PRECISION, a prospective multicenter study
Authors: S. Kobayashi, T. Takamoto, A. Shiomi, A. Takahashi, M. Shiozawa, Y. Shimizu, Y. Kagawa, D. Nobuoka, J. Yamauchi, T. Kato, E. Oki, A. Taketomi, Y. Takahashi, S. Natsume, T. Niguma, Y. Nakamura
Journal: Annals of Oncology (2023)
555MO Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13)
Authors: Y. Sunakawa, M. Shiozawa, T. Watanabe, H. Ota, H. Yasui, M. Kochi, D. Manaka, H. Ohori, T. Yamaguchi, M. Matsuura, Y. Shinohara, T. Miyake, T. Sagawa, C. Tanaka, S. Okamura, M. Takeuchi, W. Ichikawa, M. Fujii, A. Tsuji
Journal: Annals of Oncology (2023)
599P R-IMMUNE: A phase Ib/II study to evaluate safety and efficacy of atezolizumab combined with radio-chemotherapy in a preoperative setting for patients with locally advanced rectal cancer (LARC)
Authors: J. Carrasco, G. Beniuga, A. Jouret-Mourin, P. Baldin, I. Sinapi, D. Schroeder, A. De Cuyper, F. Sclafani, A. Hendlisz, J-L. van Laethem, A-S. Boulanger, G. Van Ooteghem, A. Dermine, S. Delmarcelle, N. Huyghe, I. Bar, M. van den Eynde
Journal: Annals of Oncology (2023)
568P Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial
Authors: F. Jabbar, M. Nowak, A-K. Rodewald, L. Gneo, T. Tomasevic, A. Harkin, T.J. Iveson, M.P. Saunders, R. Kerr, K.A. Oien, N. Maka, J. Hay, J. Edwards, I. Tomlinson, O.J. Sansom, C. Kelly, A. Easton, E. Domingo, V.H. Koelzer, D.N. Church
Journal: Annals of Oncology (2023)
598P Influence of the early stoma closure after low rectal cancer resection on completeness of adjuvant chemotherapy (CoCStom): A randomized, controlled multicentre trial of the AIO (AIO KRK 0113)
Authors: F. Sandra-Petrescu, F. Herrle, C. Reissfelder, P. Kienle, H. Suelberg, A. Hinke, S. Tenckhoff, R.D. Hofheinz
Journal: Annals of Oncology (2023)
601P Short-course radiotherapy based total neoadjuvant therapy combined with PD-1 inhibitor for locally advanced rectal cancer: Preliminary findings of TORCH
Authors: Y. Wang, L. Shen, J. Wan, H. Zhang, R. Wu, X. Wu, Y. Xu, S. Cai, Y. Zhao, Z. Xiang, H. Zhang, H. Wang, F. Xia, Z. Zhang
Journal: Annals of Oncology (2023)
570P Subclasses of microsatellite-instability colorectal cancer with unique molecular features and immune cell infiltration patterns
Authors: K. Wu, M. Wu, T. Luo, F. Li, L. Nunes, K. Hammarström, E. Lundin, I. Ljuslinder, A. Mezheyeuski, P-H. Edqvist, A. Löfgren-Burström, C. Zingmark, S. Edin, F. Ponten, R. Palmqvist, C. Lin, B. Glimelius, T. Sjöblom
Journal: Annals of Oncology (2023)
582P High accuracy of a blood-based multimodal ctDNA test to detect advanced neoplasms in a FIT-positive screening population
Authors: J. Vidal Barrull, A. Gómez-Alderete, J.C. Balboa, V.M. Raymond, I. Faull, B. Bellosillo Paricio, X. Bessa, C. Montagut Viladot
Journal: Annals of Oncology (2023)
577P Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer
Authors: H. Zhong, Z. Shi, H. Ren, F. Li, L. Nunes, K. Hammarström, R. Palmqvist, K. Wu, B. Glimelius, T. Sjöblom, C. Lin
Journal: Annals of Oncology (2023)
556MO A phase II clinical trial of sintilimab plus chidamide combined with or without bevacizumab in patients with MSS/pMMR metastatic colorectal cancer
Authors: F. Wang, Y. Jin, H-Y. Luo, W-L. Guan, Y. Li, F. Wang, M. Qiu, L-L. Liu, X. Hu, Y. Zhang, W. Fang, Z-X. Wang, C. Ren, D. Wang, R-H. Xu
Journal: Annals of Oncology (2023)
503MO Real-world clinical and genomic characterization of gliomas: Predictive and prognostic insights
Authors: O. Mirallas, G. Velilla, F. Ruiz-Pace, J.G. Yaringaño, T. Gorria, D. Gomez-Puerto, Á. Martínez, D.E. López Valbuena, M.A. Vaz Salgado, A. Hernandez Gonzalez, M. Aguado Sorolla, K. Raskina, M. Gonzalez Rodriguez, M. Martinez Garcia, J. Carles Galceran, C. Balana, E. Pineda, R. Dienstmann, J.M. Sepúlveda Sánchez, M. Vieito Villar
Journal: Annals of Oncology (2023)
516P Building a new prognostic score for patients with central nervous system (CNS) tumors enrolled in early phase clinical trials
Authors: K. Beshiri, A. Rousseau, S. Ponce Aix, S.N. Dumont, R. Bahleda, M. Touat, J-M. Michot, None A. Hollebecque, A. Gazzah, K. Ouali, C. Henon, C. Smolenschi, F-X. Danlos, D. Guyon, S. Ammari, C. Massard, A. Marabelle, P. Martin Romano, S. Champiat, C. Baldini
Journal: Annals of Oncology (2023)
514P Immunophenotypic profile of glioblastoma microenvironment: A cohort study
Authors: L. Gatto, C. Agostinelli, V. Di Nunno, S. Righi, A. Tosoni, F. Ambrosi, U. Vardy, S. Bartolini, L. Ranieri, S. Asioli, E. Franceschi
Journal: Annals of Oncology (2023)
508MO Spatial remodeling of the immune tumor microenvironment after radiotherapy and CXCL12 inhibition in glioblastoma in the phase I/II GLORIA trial
Authors: S. Leonardelli, J.P. Layer, L.L. Friker, R. Turiello, G. van der Voort, D. Corvino, C. Schaub, W. Müller, E. Sperk, L.C. Schmeel, K. Sahm, S. Kebir, P. Hambsch, T. Pietsch, K. Thurley, M. Glas, C. Seidel, U. Herrlinger, F.A. Giordano, M. Hölzel
Journal: Annals of Oncology (2023)
502MO Target therapy matched to genomic alterations in patients with recurrent IDH wildtype glioblastoma: A real-life cohort analysis from Veneto Institute of Oncology, Padua (Italy)
Authors: G. Cerretti, M. Padovan, C. De Toni, M. Maccari, A. Bosio, M. Caccese, M. Corrà, I. Cestonaro, A. Pittaro, A. Guerriero, M. Coppola, G. Lombardi
Journal: Annals of Oncology (2023)
CN84 Development of a unit for collection of biological samples and clinical data from cancer patients coordinated by nursing: The translational oncology research project (INTRON)
Authors: M.P. Andueza, E. Navarcorena Zabalza, Y. Iragorri Barberena, L. Soria Royo, S. Chocarro Martin, M. Ayensa Burgui, I. Gracia Ilundain, I. Navamuel Andueza, J.L. Perez Gracia, A. Ojer Perea, M. Ocon
Journal: Annals of Oncology (2023)
595P The DUREC trial: Durvalumab plus total neoadjuvant therapy in locally advanced rectal cancer - a multicenter, single-arm, phase II study (GEMCAD-1703)
Authors: J. Capdevila Castillon, V. Alonso, I. Macias Declara, M. Melian, J. Gallego Plazas, R. Vera, M.C. Riesco Martinez, J. Maurel, B. Grana Suarez, J. Hernando, A. Garcia Alvarez, B. Navalpotro, G. Soler Gonzalez, E. Polo, A. Garcia Fadrique, E. Espin, C. Fernandez Martos, G. Villacampa Javierre, F. Losa
Journal: Annals of Oncology (2023)